{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:40:13Z","timestamp":1657784413992},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T00:00:00Z","timestamp":1479340800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Medicine and Health Science Technology Development Plan of Shandong Province","award":["2013WS0103"],"award-info":[{"award-number":["2013WS0103"]}]},{"name":"Shandong Provinval Natural Science foundation","award":["ZR2014HQ028"],"award-info":[{"award-number":["ZR2014HQ028"]}]},{"name":"Provincial science and technology development plan of Shandong","award":["2015GSF118063"],"award-info":[{"award-number":["2015GSF118063"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40261-016-0475-y","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T11:36:55Z","timestamp":1479382615000},"page":"135-153","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Hongxin","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linhai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,17]]},"reference":[{"issue":"2","key":"475_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65(2):87\u2013108. doi: 10.3322\/caac.21262 .","journal-title":"CA: Cancer J Clin."},{"issue":"4","key":"475_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","volume":"64","author":"CE DeSantis","year":"2014","unstructured":"DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA: Cancer J Clin. 2014;64(4):252\u201371. doi: 10.3322\/caac.21235 .","journal-title":"CA: Cancer J Clin."},{"issue":"7015","key":"475_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers C. Targeted cancer therapy. Nature. 2004;432(7015):294\u20137. doi: 10.1038\/nature03095 .","journal-title":"Nature."},{"issue":"5578","key":"475_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein IB. Cancer. Addiction to oncogenes\u2014the Achilles heel of cancer. Sci (New York, NY). 2002;297(5578):63\u20134. doi: 10.1126\/science.1073096 .","journal-title":"Sci (New York, NY)"},{"issue":"13","key":"475_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/jnci\/djs258","volume":"104","author":"D Yee","year":"2012","unstructured":"Yee D. Insulin\u2013like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst. 2012;104(13):975\u201381. doi: 10.1093\/jnci\/djs258 .","journal-title":"J Natl Cancer Inst."},{"key":"475_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addr.2015.12.005","volume":"98","author":"KL Nastiuk","year":"2016","unstructured":"Nastiuk KL, Krolewski JJ. Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev. 2016;98:35\u201340. doi: 10.1016\/j.addr.2015.12.005 .","journal-title":"Adv Drug Deliv Rev."},{"issue":"4930","key":"475_CR7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1126\/science.2683075","volume":"246","author":"AB Pardee","year":"1989","unstructured":"Pardee AB. G1 events and regulation of cell proliferation. Sci (New York, NY). 1989;246(4930):603\u20138.","journal-title":"Sci (New York, NY)"},{"issue":"2","key":"475_CR8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0092-8674(91)90638-F","volume":"64","author":"M Cross","year":"1991","unstructured":"Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell. 1991;64(2):271\u201380.","journal-title":"Cell."},{"issue":"19","key":"475_CR9","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1158\/1078-0432.ccr-14-2518","volume":"21","author":"WT Iams","year":"2015","unstructured":"Iams WT, Lovly CM. Molecular pathways: clinical applications and future direction of insulin\u2013like growth factor\u20131 receptor pathway blockade. Clin Cancer Res. 2015;21(19):4270\u20137. doi: 10.1158\/1078-0432.ccr-14-2518 .","journal-title":"Clin Cancer Res"},{"issue":"34","key":"475_CR10","doi-asserted-by":"crossref","first-page":"21172","DOI":"10.1016\/S0021-9258(17)45342-7","volume":"265","author":"AJ Stewart","year":"1990","unstructured":"Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin\u2013like growth factors and the type I insulin\u2013like growth factor receptor in the estrogen\u2013stimulated proliferation of human breast cancer cells. J Biol Chem. 1990;265(34):21172\u20138.","journal-title":"J Biol Chem."},{"key":"475_CR11","doi-asserted-by":"publisher","unstructured":"Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado\u2013Heinsohn E, Osborne CK et al. Enhancement of insulin\u2013like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate\u20131 expression in vitro and in vivo. Mol Endocrinol (Baltimore, Md). 1999;13(5):787\u201396. doi: 10.1210\/mend.13.5.0274 .","DOI":"10.1210\/mend.13.5.0274"},{"issue":"18 Pt 2","key":"475_CR12","doi-asserted-by":"publisher","first-page":"5549s","DOI":"10.1158\/1078-0432.ccr-07-1109","volume":"13","author":"EK Rowinsky","year":"2007","unstructured":"Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC\u2013A12, a human IgG1 monoclonal antibody to the insulin\u2013like growth factor I receptor. Clin Cancer Res. 2007;13(18 Pt 2):5549s\u201355s. doi: 10.1158\/1078-0432.ccr-07-1109 .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"475_CR13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/annonc\/mds511","volume":"24","author":"VM Macaulay","year":"2013","unstructured":"Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, et al. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin\u2013like growth factor receptor (IGF\u20131R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol. 2013;24(3):784\u201391. doi: 10.1093\/annonc\/mds511 .","journal-title":"Ann Oncol"},{"issue":"18","key":"475_CR14","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1158\/1078-0432.ccr-10-2979","volume":"17","author":"A Naing","year":"2011","unstructured":"Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011;17(18):6052\u201360. doi: 10.1158\/1078-0432.ccr-10-2979 .","journal-title":"Clin Cancer Res"},{"issue":"6","key":"475_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bcp.12228","volume":"77","author":"H Ma","year":"2014","unstructured":"Ma H, Zhang T, Shen H, Cao H, Du J. The adverse events profile of anti\u2013IGF\u20131R monoclonal antibodies in cancer therapy. Br J Clin Pharmacol. 2014;77(6):917\u201328. doi: 10.1111\/bcp.12228 .","journal-title":"Br J Clin Pharmacol."},{"issue":"7","key":"475_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1517\/13543780903055049","volume":"18","author":"KP McKian","year":"2009","unstructured":"McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs. 2009;18(7):1025\u201333. doi: 10.1517\/13543780903055049 .","journal-title":"Expert Opin Investig Drugs."},{"issue":"24","key":"475_CR17","first-page":"8912","volume":"63","author":"D Burtrum","year":"2003","unstructured":"Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin\u2013like growth factor I receptor blocks ligand\u2013dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003;63(24):8912\u201321.","journal-title":"Cancer Res."},{"issue":"4","key":"475_CR18","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/0008-5472.can-05-3126","volume":"66","author":"D Sachdev","year":"2006","unstructured":"Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down\u2013regulation of insulin receptor by antibodies against the type I insulin\u2013like growth factor receptor: implications for anti\u2013insulin\u2013like growth factor therapy in breast cancer. Cancer Res. 2006;66(4):2391\u2013402. doi: 10.1158\/0008-5472.can-05-3126 .","journal-title":"Cancer Res."},{"issue":"3","key":"475_CR19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1568009023333863","volume":"2","author":"Y Wang","year":"2002","unstructured":"Wang Y, Sun Y. Insulin\u2013like growth factor receptor\u20131 as an anti\u2013cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets. 2002;2(3):191\u2013207.","journal-title":"Curr Cancer Drug Targets."},{"issue":"27","key":"475_CR20","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1200\/jco.2010.30.4154","volume":"28","author":"DL Reidy","year":"2010","unstructured":"Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, et al. Randomized, phase II study of the insulin\u2013like growth factor\u20131 receptor inhibitor IMC\u2013A12, with or without cetuximab, in patients with cetuximab\u2013 or panitumumab\u2013refractory metastatic colorectal cancer. J Clin Oncol. 2010;28(27):4240\u20136. doi: 10.1200\/jco.2010.30.4154 .","journal-title":"J Clin Oncol."},{"issue":"4","key":"475_CR21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(13)70049-4","volume":"14","author":"GK Schwartz","year":"2013","unstructured":"Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, et al. Cixutumumab and temsirolimus for patients with bone and soft\u2013tissue sarcoma: a multicentre, open\u2013label, phase 2 trial. Lancet Oncol. 2013;14(4):371\u201382.","journal-title":"Lancet Oncol"},{"issue":"19","key":"475_CR22","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1002\/cncr.28744","volume":"120","author":"PA Philip","year":"2014","unstructured":"Philip PA, Goldman B, Ramanathan RK, et al. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer. 2014;120(19):2980\u20135. doi: 10.1002\/cncr.28744 .","journal-title":"Cancer."},{"issue":"14","key":"475_CR23","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1200\/jco.2014.59.4127","volume":"33","author":"EY Yu","year":"2015","unstructured":"Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, et al. SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2015;33(14):1601\u20138. doi: 10.1200\/jco.2014.59.4127 .","journal-title":"J Clin Oncol."},{"issue":"3","key":"475_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pbc.25334","volume":"62","author":"LM Wagner","year":"2015","unstructured":"Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2015;62(3):440\u20134. doi: 10.1002\/pbc.25334 .","journal-title":"Pediatr Blood Cancer."},{"issue":"5_suppl","key":"475_CR25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/jco.2012.30.5_suppl.97","volume":"30","author":"M Hussain","year":"2012","unstructured":"Hussain M, Rathkopf DE, Liu G, Armstrong AJ, Kelly WK, Ferrari AC, et al. A phase II randomized study of cixutumumab (IMC\u2013A12: CIX) or ramucirumab (IMC\u20131121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate\u2013resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel. J Clin Oncol. 2012;30(5_suppl):97.","journal-title":"J Clin Oncol."},{"issue":"2","key":"475_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1078-0432.ccr-15-0588","volume":"22","author":"WJ Gradishar","year":"2016","unstructured":"Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, et al. Clinical and translational results of a phase II, randomized trial of an anti\u2013IGF\u20131R (Cixutumumab) in women with breast cancer that progressed on endocrine therapy. Clin Cancer Res. 2016;22(2):301\u20139. doi: 10.1158\/1078-0432.ccr-15-0588 .","journal-title":"Clin Cancer Res."},{"issue":"13","key":"475_CR27","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1002\/cncr.29308","volume":"121","author":"NH Hanna","year":"2015","unstructured":"Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, et al. Three\u2013arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non\u2013small cell lung cancer (NSCLC) patients who will not receive bevacizumab\u2013based therapy: an Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. 2015;121(13):2253\u201361. doi: 10.1002\/cncr.29308 .","journal-title":"Cancer."},{"issue":"2","key":"475_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/JTO.0b013e31823c5b11","volume":"7","author":"A Weickhardt","year":"2012","unstructured":"Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, et al. A phase I\/II study of erlotinib in combination with the anti\u2013insulin\u2013like growth factor\u20131 receptor monoclonal antibody IMC\u2013A12 (cixutumumab) in patients with advanced non\u2013small cell lung cancer. J Thorac Oncol. 2012;7(2):419\u201326. doi: 10.1097\/JTO.0b013e31823c5b11 .","journal-title":"J Thorac Oncol"},{"issue":"3","key":"475_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/jco.2011.37.4355","volume":"30","author":"S Malempati","year":"2012","unstructured":"Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30(3):256\u201362. doi: 10.1200\/jco.2011.37.4355 .","journal-title":"J Clin Oncol"},{"key":"475_CR30","doi-asserted-by":"publisher","unstructured":"Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P et al. An open\u2013label, phase 2 study evaluating the efficacy and safety of the anti\u2013IGF\u20131R antibody cixutumumab in patients with previously treated advanced or metastatic soft\u2013tissue sarcoma or Ewing family of tumours. Eur J Cancer (Oxford, England: 1990). 2013;49(15):3219\u201328. doi: 10.1016\/j.ejca.2013.06.010 .","DOI":"10.1016\/j.ejca.2013.06.010"},{"issue":"3","key":"475_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pbc.24605","volume":"61","author":"B Weigel","year":"2014","unstructured":"Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2014;61(3):452\u20136. doi: 10.1002\/pbc.24605 .","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"475_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s1470-2045(13),70596-5","volume":"15","author":"A Rajan","year":"2014","unstructured":"Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15(2):191\u2013200. doi: 10.1016\/s1470-2045(13),70596-5 .","journal-title":"Lancet Oncol."},{"issue":"2","key":"475_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jhep.2013.09.008","volume":"60","author":"GK Abou-Alfa","year":"2014","unstructured":"Abou-Alfa GK, Capanu M, O\u2019Reilly EM, Ma J, Chou JF, Gansukh B, et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol. 2014;60(2):319\u201324. doi: 10.1016\/j.jhep.2013.09.008 .","journal-title":"J Hepatol."},{"issue":"7","key":"475_CR34","first-page":"S12","volume":"29","author":"JP Dean","year":"2011","unstructured":"Dean JP, Montgomery RB, Wan J, Cohen P, Haugk K, Corman JM, et al. On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high\u2013risk prostate cancer: a phase II trial. J Clin Oncol. 2011;29(7):S12.","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"475_CR35","doi-asserted-by":"crossref","first-page":"TPS221","DOI":"10.1200\/jco.2011.29.15_suppl.tps221","volume":"29","author":"A Argiris","year":"2011","unstructured":"Argiris A, Lee J, Schiller JH, Pittsburgh UO, Pittsburgh Institute DFC, et al. E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). J Clin Oncol. 2011;29(15_suppl):TPS221.","journal-title":"J Clin Oncol"},{"issue":"9","key":"475_CR36","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1158\/1078-0432.ccr-12-0061","volume":"18","author":"A Naing","year":"2012","unstructured":"Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing\u2019s sarcoma family tumors. Clin Cancer Res. 2012;18(9):2625\u201331. doi: 10.1158\/1078-0432.ccr-12-0061 .","journal-title":"Clin Cancer Res"},{"issue":"12","key":"475_CR37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/jto.0000000000000005","volume":"8","author":"GV Scagliotti","year":"2013","unstructured":"Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, et al. An open\u2013label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first\u2013line treatment of patients with advanced\u2013stage non\u2013small\u2013cell lung cancer. J Thorac Oncol. 2013;8(12):1529\u201337. doi: 10.1097\/jto.0000000000000005 .","journal-title":"J Thorac Oncol"},{"key":"475_CR38","unstructured":"Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage\u2013small cell lung cancer (ES\u2013SCLC) (ECOG 1508). J Clin Oncol. 2013;31(15_suppl), abstract 7508."},{"key":"475_CR39","unstructured":"Glisson BS, Tseng JE, Marur S. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent\/metastatic squamous cancer of head and neck. J Clin Oncol. 2013;31(15_suppl), abstract 6030."},{"key":"475_CR40","unstructured":"Cohen SJ, Feng Y, Catalano PJ, Mitchell EP, O\u2019Dwyer PJ, Lubner SJ et al. E2208: Randomized phase II study of paclitaxel with or without the anti\u2013IGF\u2013IR antibody cixutumumab (IMC\u2013A12) as second\u2013line treatment for patients with metastatic esophageal or GE junction cancer. J Clin Oncol. 2014;32(15_suppl), abstract 3020."},{"key":"475_CR41","unstructured":"Haluska P, Bernath AM, Ballman KV, Dueck AC, Linden HM, Goetz MP et al. Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and\/or a taxane: NCCTG N0733 (Alliance). 2014;32(15_suppl), abstract 632."},{"key":"475_CR42","unstructured":"Clinicaltrials.gov. IMC-A12 with mitotane vs mitotane alone in recurrent, metastatic, or primary ACC that cannot be removed by surgery. 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00778817?term=NCT00778817&rank=1 ."},{"key":"475_CR43","unstructured":"Clinicaltrials.gov. Cixutumumab and Temsirolimus in treating patients with locally recurrent or metastatic breast cancer. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00699491?term=NCT00699491&rank=1 ."},{"key":"475_CR44","unstructured":"Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin\u2013like growth factor\u20131 receptor (IGF\u2013IR), as monotherapy in patients with metastastic, asymptomatic castration\u2013resistant prostate ca. J Clin Oncol. 2009;27(15_suppl), abstract 5142."},{"key":"475_CR45","unstructured":"Clinicaltrials.gov. Cixutumumab in treating patients with metastatic melanoma of the eye. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01413191?term=NCT01413191&rank=1 ."},{"key":"475_CR46","unstructured":"Clinicaltrials.gov. Phase II study of IMC\u2013A12 in patients with mesothelioma who have been previously treated with chemotherapy. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01160458?term=NCT01160458&rank=1 ."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0475-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0475-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0475-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:07:53Z","timestamp":1657757273000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0475-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,17]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0475-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,17]]}}}